| Item Type | Name |
|
Concept
|
Head and Neck Neoplasms
|
|
Academic Article
|
Phase I study of concomitant chemoradiotherapy with paclitaxel, fluorouracil, and hydroxyurea with granulocyte colony-stimulating factor support for patients with poor-prognosis cancer of the head and neck.
|
|
Academic Article
|
Oral chemotherapy in head and neck cancer.
|
|
Academic Article
|
Integration of taxanes into primary chemotherapy for squamous cell carcinoma of the head and neck: promise fulfilled?
|
|
Academic Article
|
Benefits of chemotherapy in head and neck cancer.
|
|
Academic Article
|
Workshop report: organ preservation strategies in advanced head and neck cancer--current status and future directions.
|
|
Academic Article
|
A phase I-II study of concomitant chemoradiotherapy with paclitaxel (one-hour infusion), 5-fluorouracil and hydroxyurea with granulocyte colony stimulating factor support for patients with poor prognosis head and neck cancer.
|
|
Academic Article
|
Reduction of distant metastases in head and neck cancer with concomitant chemotherapy.
|
|
Academic Article
|
Phase I study of eniluracil, a dihydropyrimidine dehydrogenase inactivator, and oral 5-fluorouracil with radiation therapy in patients with recurrent or advanced head and neck cancer.
|
|
Academic Article
|
Oral 5-FU alternatives for the treatment of head and neck cancer.
|
|
Academic Article
|
Paclitaxel, 5-fluorouracil, hydroxyurea, and concomitant radiation therapy for poor-prognosis head and neck cancer.
|
|
Academic Article
|
Weekly carboplatin and paclitaxel followed by concomitant paclitaxel, fluorouracil, and hydroxyurea chemoradiotherapy: curative and organ-preserving therapy for advanced head and neck cancer.
|
|
Academic Article
|
Organ preservation for advanced head and neck cancer concomitant chemoradiation.
|
|
Academic Article
|
Induction chemotherapy followed by concomitant TFHX chemoradiotherapy with reduced dose radiation in advanced head and neck cancer.
|
|
Academic Article
|
Competing causes of death and second primary tumors in patients with locoregionally advanced head and neck cancer treated with chemoradiotherapy.
|
|
Academic Article
|
Neck dissection in the combined-modality therapy of patients with locoregionally advanced head and neck cancer.
|
|
Academic Article
|
Is patient travel distance associated with survival on phase II clinical trials in oncology?
|
|
Academic Article
|
Management of sarcomas of the head and neck.
|
|
Academic Article
|
Phase II studies of bryostatin-1 in patients with advanced sarcoma and advanced head and neck cancer.
|
|
Academic Article
|
Multicenter randomized Phase II study of paclitaxel (1-hour infusion), fluorouracil, hydroxyurea, and concomitant twice daily radiation with or without erythropoietin for advanced head and neck cancer.
|
|
Academic Article
|
Patterns of failure, prognostic factors and survival in locoregionally advanced head and neck cancer treated with concomitant chemoradiotherapy: a 9-year, 337-patient, multi-institutional experience.
|
|
Academic Article
|
The role of inhibitors of the epidermal growth factor in management of head and neck cancer.
|
|
Academic Article
|
Concurrent chemoradiotherapy for head and neck cancer.
|
|
Academic Article
|
High survival and organ function rates after primary chemoradiotherapy for intermediate-stage squamous cell carcinoma of the head and neck treated in a multicenter phase II trial.
|
|
Academic Article
|
Epidermal growth factor receptor inhibitor gefitinib added to chemoradiotherapy in locally advanced head and neck cancer.
|
|
Academic Article
|
Head and neck cancer in 2010: Maximizing survival and minimizing toxicity.
|
|
Academic Article
|
Radiotherapy: Accelerated radiotherapy for HNSCC in developing countries.
|
|
Academic Article
|
Management of recurrent head and neck cancer: recent progress and future directions.
|
|
Academic Article
|
Swallowing function in patients with head and neck cancer prior to treatment.
|
|
Academic Article
|
Phase II trial of aminocamptothecin (9-AC/DMA) in patients with advanced squamous cell head and neck cancer.
|
|
Academic Article
|
Concomitant infusional paclitaxel and fluorouracil, oral hydroxyurea, and hyperfractionated radiation for locally advanced squamous head and neck cancer.
|
|
Academic Article
|
Site of disease and treatment protocol as correlates of swallowing function in patients with head and neck cancer treated with chemoradiation.
|
|
Academic Article
|
Phase II trial of gefitinib 250 mg daily in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.
|
|
Academic Article
|
A randomized validation study comparing embedded versus extracted FACT Head and Neck Symptom Index scores.
|
|
Academic Article
|
Induction chemotherapy and concurrent chemoradiotherapy for locoregionally advanced head and neck cancer: a multi-institutional phase II trial investigating three radiotherapy dose levels.
|
|
Academic Article
|
Docetaxel and irinotecan in recurrent or metastatic head and neck cancer: a phase 2 trial of the Eastern Cooperative Oncology Group.
|
|
Academic Article
|
A randomized phase II study of cetuximab every 2 weeks at either 500 or 750 mg/m2 for patients with recurrent or metastatic head and neck squamous cell cancer.
|
|
Academic Article
|
Overview of head and neck cancer.
|
|
Academic Article
|
Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer.
|
|
Academic Article
|
Reply to s. Chakraborty et al.
|
|
Academic Article
|
Current clinical immunotherapeutic approaches for head and neck cancer.
|
|
Academic Article
|
Targeting pathways mediating resistance to anti-EGFR therapy in squamous cell carcinoma of the head and neck.
|
|
Academic Article
|
Weekly docetaxel (D) and irinotecan (I) in patients (pts) with recurrent or metastatic head and neck cancer (HNC): A phase II trial of the Eastern Cooperative Oncology Group (ECOG).
|
|
Academic Article
|
Integration of gefitinib (G), into a concurrent chemoradiation (CRT) regimen followed by G adjuvant therapy in patients with locally advanced head and neck cancer (HNC) - a Phase II Trial.
|
|
Academic Article
|
Couple-based communication intervention for head and neck cancer: a randomized pilot trial.
|
|
Academic Article
|
Programmed Death Ligand-1 Combined Positive Score Concordance and Interrater Reliability in Primary Tumors and Synchronous Lymph Node Metastases in Resected Cases of p16+ Oropharyngeal Squamous Cell Carcinoma.
|